
Frequency Therapeutics FREQ
Annual report 2025
added 03-12-2026
Frequency Therapeutics General and Administrative Expenses 2011-2026 | FREQ
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Frequency Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.2 M | 30.5 M | 27.3 M | 16.8 M | 37.2 M | 27.1 M | 30.8 M | 7.06 M | 4.34 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.2 M | 4.34 M | 23.3 M |
Quarterly General and Administrative Expenses Frequency Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.51 M | 7.63 M | 7.83 M | - | 7.33 M | 6.99 M | 7.88 M | - | 5.14 M | 5.28 M | 5.39 M | - | 8.56 M | 8 M | 9.48 M | - | 9.33 M | 9.5 M | 9.74 M | - | 6.51 M | 5.96 M | 6.25 M | - | 4.27 M | 3.1 M | 2.47 M | - | 1.51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.74 M | 1.51 M | 6.58 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
4.31 M | $ 2.25 | 1.81 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
286 M | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
5.94 M | $ 0.44 | -16.64 % | $ 5.04 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
63.1 M | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
15.2 M | $ 10.14 | -0.29 % | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
14.2 M | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
14 M | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
191 M | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
73.5 M | $ 49.15 | -0.73 % | $ 4.42 B | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
13.8 M | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CytomX Therapeutics
CTMX
|
29.8 M | $ 4.4 | -3.51 % | $ 607 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Citius Pharmaceuticals
CTXR
|
18.2 M | $ 0.86 | 0.67 % | $ 5.79 M | ||
|
Cue Biopharma
CUE
|
16.2 M | $ 0.18 | -1.61 % | $ 17.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Cyclerion Therapeutics
CYCN
|
5.34 M | $ 4.15 | -32.52 % | $ 10.4 M | ||
|
Daré Bioscience
DARE
|
8.76 M | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
DBV Technologies S.A.
DBVT
|
32.8 M | $ 20.36 | -3.32 % | $ 2.84 B | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Denali Therapeutics
DNLI
|
105 M | $ 19.38 | -6.15 % | $ 3.19 B | ||
|
Dyadic International
DYAI
|
890 K | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
43.8 M | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
3.65 M | - | -52.27 % | $ 4.45 M |